Aligos Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	31.52	2.19	3.95	15.53	13.91	4.36
Revenue Growth	893.01%	-44.59%	-74.60%	11.66%	219.04%	-
Cost of Revenue	88.38	69.45	70.27	73.04	85.08	104.15
Gross Profit	-56.86	-67.27	-66.32	-57.51	-71.17	-99.79
Selling, General & Admin	22.14	20.72	22.83	29.89	26.41	28.53
Operating Expenses	22.14	20.72	22.83	29.89	26.41	28.53
Operating Income	-78.99	-87.99	-89.15	-87.4	-97.58	-128.32
Interest & Investment Income	1.31	2.16	1.67	4.3	1.52	0.24
Currency Exchange Gain (Loss)	0.2	0.2	-	-0.05	-0.04	-0.01
Other Non Operating Income (Expenses)	4.74	61.74	-43.4	-3.01	0.16	-0.1
EBT Excluding Unusual Items	-72.75	-23.88	-130.88	-86.16	-95.94	-128.19
Asset Writedown	-	-	-	-0.72	-	-
Pretax Income	-72.75	-23.88	-130.88	-86.88	-95.94	-128.19
Income Tax Expense	3.21	0.31	0.33	0.8	0.11	0.14
Net Income	-75.96	-24.19	-131.21	-87.68	-96.05	-128.33
Net Income to Common	-75.96	-24.19	-131.21	-87.68	-96.05	-128.33
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	10	10	6	3	2	2
Shares Outstanding (Diluted)	10	10	6	3	2	2
Shares Change	32.81%	57.79%	144.38%	50.10%	7.12%	299.03%
EPS (Basic)	-7.30	-2.45	-20.94	-34.20	-56.24	-80.50
EPS (Diluted)	-7.31	-2.45	-20.94	-34.20	-56.25	-80.50
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-94.52	-82.94	-80.87	-79.02	-80.33	-116.55
Free Cash Flow Per Share	-9.09	-8.39	-12.91	-30.82	-47.04	-73.11
Operating Margin	-250.63%	-4024.93%	-2259.92%	-562.84%	-701.66%	-2943.82%
Profit Margin	-241.01%	-1106.72%	-3326.01%	-564.62%	-690.63%	-2944.07%
Free Cash Flow Margin	-299.90%	-3794.15%	-2050.01%	-508.83%	-577.64%	-2673.87%
EBITDA	-77.92	-87.06	-88.13	-85.84	-95.27	-125.3
D&A For EBITDA	1.08	0.93	1.03	1.56	2.31	3.02
EBIT	-78.99	-87.99	-89.15	-87.4	-97.58	-128.32

SEC Filings: 10-K · 10-Q